Table 1 Patient baseline characteristics overall and of the choline alfoscerate-exposed group versus the nonexposed group
Characteristics, N (%) 1 | Overall | CA-exposed | Nonexposed | p2 |
|---|---|---|---|---|
Number of patients (%)3 | 11,463 | 2173 (19.0) | 9290 (81.0) | - |
Demographic | ||||
Age at baseline, years - Mean (SD) | 78.3 (6.3) | 77.5 (6.0) | 78.5 (6.4) | < 0.001* |
Sex: Female | 8338 (72.7) | 1564 (72.0) | 6774 (72.9) | 0.389 |
High insurance premiums | 6921 (60.4) | 1266 (58.3) | 5655 (60.9) | 0.027* |
Comorbidities | ||||
Hypertension | 8859 (77.3) | 1697 (78.1) | 7162 (77.1) | 0.33 |
Dyslipidemia/ atherosclerosis | 5211 (45.5) | 1097 (50.5) | 4114 (44.3) | < 0.001* |
Diabetes mellitus | 4449 (38.8) | 877 (40.4) | 3572 (38.4) | 0.105 |
Depression | 3104 (27.1) | 599 (27.6) | 2505 (27.0) | 0.587 |
COPD | 2770 (24.2) | 550 (25.3) | 2220 (23.9) | 0.174 |
Anemia | 1539 (13.4) | 282 (13.0) | 1257 (13.5) | 0.518 |
Cancer | 1399 (12.2) | 284 (13.1) | 1115 (12.0) | 0.183 |
Heart failure | 1283 (11.2) | 226 (10.4) | 1057 (11.4) | 0.207 |
Chronic renal failure | 385 (3.4) | 67 (3.1) | 318 (3.4) | 0.468 |
Concurrent agents | ||||
Antihypertensive | 9373 (81.8) | 1820 (83.8) | 7553 (81.3) | 0.008* |
Antithrombotic | 8174 (71.3) | 1663 (76.5) | 6511 (70.1) | < 0.001* |
Antidepressant | 5714 (49.8) | 1132 (52.1) | 4582 (49.3) | 0.021* |
Lipid modifying | 4888 (42.6) | 1022 (47.0) | 3866 (41.6) | < 0.001* |
Antidiabetic | 2897 (25.3) | 562 (25.9) | 2335 (25.1) | 0.499 |
Dementia treatment | ||||
Donepezil prescription | 8986 (78.4) | 1744 (80.3) | 7242 (78.0) | 0.020* |